COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

Protocol No
ECOG-EA2186-GIANT
Principal Investigator
Mandana Kamgar
Phase
II
Summary
This study is being done to answer the following question: Which of two treatment combinations, Gemcitabine and Nab-paclitaxel or 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan, is more effective at lengthening the period of time that less fit patients over the age of 70 years with metastatic pancreatic cancer (mPCA) live? We are doing this study because we want to find out what the best approach to lengthen the lives of "vulnerable" patients over the age of 70 with mPCA is. Currently, there is no known best practice for this type of patient.
Description
Comparing Two Treatment Combinations for Older Patients With Pancreatic Cancer That Has Spread
Participating Institutions
Drexel Town Center
Froedtert Menomonee Falls Hospital
Froedtert Hospital
Froedtert West Bend Hospital
Status
OPEN TO ACCRUAL